A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis

Study Summary

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.

Conditions

Acute Gastroenteritis Norovirus Acute Gastroenteritis

Interventions / Drugs

mRNA-1403 Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment37864 participants

Primary Completion—

Lead SponsorModernaTX, Inc.

Data Retrieved2026-04-11 02:55:38.209209+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.